Target Audience
This activity was developed for oncologists, pathologists, oncology nurse practitioners, nurses, physician associates, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with non-small cell lung cancer (NSCLC).
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Evaluate current first-line treatment options in patients with ROS1 rearranged NSCLC
- Optimize ROS1 targeted tyrosine kinase inhibitors in individual patients consistent with current evidence-based guideline recommendations
- Assess recent clinical data for emerging therapies in ROS1 rearranged NSCLC
Faculty
Jonathan Dowell, MD Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates
this enduring activity for a maximum of
0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation
in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based
activity for a maximum of
0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity
completion.
Annenberg Center for Health Sciences at Eisenhower designates
this enduring activity for a maximum of
0.75 ANCC contact hours.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance,
independence, objectivity, and scientific rigor in all programming. All individuals with the
potential to impact the content of an accredited education activity are expected to identify and
reference off-label product use and disclose relationships with ACCME-defined ineligible
companies.
The Annenberg Center for Health Sciences assesses relevant relationships with its instructors,
planners, managers, and other individuals who are in a position to control the content of CE
activities. All relevant relationships that are identified are thoroughly vetted by the
Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity,
and patient care recommendations. The Annenberg Center is committed to providing its learners
with high-quality CE activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel
documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the
following disclosures have been made:
Disclosures
Jonathan Dowell, MD Advisory Board: Catalyst, Regeneron, Takeda
The faculty for this enduring activity has disclosed that there will be
discussion about the use of products for non-FDA approved applications.
Additional Content Planners
Jada Dillner, PA (Peer Reviewer)No significant relationships to disclose.
Chris Elder, PharmD, BCOP (Medical Writer)
Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and Pharmacosmos
Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)No significant relationships to disclose.
All other individuals in a position to control the content of this CE activity have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
The ideas and opinions presented in this educational activity are those of the faculty and do not
necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational
activities, we encourage practitioners to use their own judgment in treating and addressing the
needs of each individual patient, taking into account that patient's unique clinical situation.
The Annenberg Center disclaims all liability and cannot be held responsible for any problems
that may arise from participating in this activity or following treatment recommendations
presented.
This activity is supported by an educational grant from Bristol Myers Squibb.
This activity is an online enduring material. Successful completion is achieved by reading
and/or viewing the material,
reflecting on its implications in your practice, and completing the assessment
component.
The estimated time to complete the activity is
0.75 hours.
This activity was originally released on
2024-09-30 and is eligible for credit through
2025-09-30.
Our Policy on Privacy
Annenberg Center for Health Sciences respects your privacy. We don’t share information you
give us, or have the need to share this information in the normal course of providing the
services and information you may request. If there should be a need or request to share this
information, we will do so only with your explicit permission. See Privacy Statement and other
information at https://annenberg.net/pages/privacyPolicy.php
Contact Information
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
[email protected]
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM,
Pacific Time, Monday – Friday
.jpg)
